Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy.

Journal: JHEP reports : innovation in hepatology
Published Date: May 8, 2025

Abstract

BACKGROUND & AIMS: Fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) is a prognostic indicator and clinical trial efficacy endpoint. Second-harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy images unstained tissue sections and, when integrated with artificial intelligence models, generates a continuous fibrosis value (qFibrosis) and ordinal qFibrosis stage. The impact of biopsy size and location on the accuracy of these approaches has not been assessed in MASLD, leaving quality assurance procedures undefined.

Authors

  • Daniel T Field
    Edinburgh Pathology, University of Edinburgh, Edinburgh, UK.
  • Yayun Ren
    Hangzhou Choutu Tech. Co., Ltd., Hangzhou, China.
  • Kutbuddin Akbary
    Histoindex Pte. Ltd., Singapore.
  • Elaine Chng
    HistoIndex Pte. Ltd., Singapore.
  • Dean Tai
    HistoIndex Pte Ltd, Singapore.
  • Nikolai V Naoumov
    Division of Medicine, University College London, London, UK.
  • David E Kleiner
    Laboratory of Pathology National Cancer Institute, National Institutes of Health Bethesda MD.
  • Jonathan A Fallowfield
    Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
  • Timothy J Kendall
    Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh, United Kingdom.
  • Arun J Sanyal
    Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals